[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neuropathic-mucopolysaccharidosis-type-ii":3},{"name":4,"total":5,"trials":6,"biomarkers":15,"states":16},"Neuropathic Mucopolysaccharidosis Type II",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06075537","An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007",[11],"Phase 2\u002FPhase 3","ENROLLING_BY_INVITATION","2026-08-03T02:37:16.921019Z","2026-06-16T05:54:08.100664Z",[],[]]